Furthermore, the tumor phenotypes and POLE/POLD1 expression levels correlate with tumor mutation burden and tumor driver gene expression according to an analysis of a panel of mutations in 1,392 Chinese patients with cancer (Yao et al., 2019). This evidence concerns the gene POLD1 and cancer.